Concurrent Chemoradiation With BMX-001 In Patients With Head And Neck Cancer

Short Title: NRG-CC013

Enrollment Status: Recruiting

NCT #: NCT06532279

Specialty Area: Oncology

Conditions Studied: Head and Neck Squamous Cell Carcinoma; Oral Mucositis

Age Groups: Adult; Older Adult

Phase: II

Study Information

Summary / Purpose

To find out if adding BMX-001, a radioprotective drug, to usual symptom management helps reduce oral mucositis (painful mouth sores and inflammation) in people receiving chemoradiation for head and neck cancer.

Study Type: Interventional

Accepts Healthy Volunteers: No

Who Can Participate

Eligibility Criteria:

Adults 18+ years of age
Diagnosed with head and neck cancer
Receiving chemoradiation therapy as part of treatment
No significant heart or vascular disease

What's Involved

Participation in the study will include:

Standard chemoradiation therapy with cisplatin given intravenously (IV) and radiation
Supportive care with the study medication, BMX-001, or a placebo
Blood and imaging tests (CT, MRI) to monitor response to treatment
Questionnaires

Principal Investigator

Abhinand Peddada, MD

Radiation Oncology

A Member of

(775) 982–5638

William N. Pennington Cancer Institute

View Provider

Additional Information

Location: Renown Health, Office of Clinical Research
Address:

1500 E 2nd St. Reno, NV 89502

General Research: 775-982-3646
Oncology Research: 775-982-5050
Email: Renown-CRD@renown.org

Complete Study Details: https://clinicaltrials.gov/study/NCT06532279

Disclaimer: This listing gives you general information about the study and isn't part of the official consent process. If you decide to learn more, the research team will talk with you and check if you meet any additional requirements to join the study.

Health & Wellness eNews